ATyr Pharma
aTyr Pharma is a public biotherapeutics company ( ) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
aTyr Pharma is a public biotherapeutics company ( ) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need.
ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 20051 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1359326011 under CC BY-SA 4.0; modifications have been made.
References
- ↩Wikipedia “ATyr Pharma” date of foundation (×1) · confidence 0.95 revision URL